Dr. John J. Ryan, MBBCHBAO
Cardiology (Cardiovascular Disease Physician)
Division Of Cardiology University Of Utah, 50 North Medical Dr
Salt Lake City, UT 84132
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,501
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
UT license 8417065-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
- St Mark's Hospital Salt Lake City, UT
- Holy Cross Hospital-Jordan Valley West Jordan, UT
- Memorial Hospital Sweetwater County Rock Springs, WY
- Holy Cross Hospital - Salt Lake Salt Lake City, UT
Medical groups
- University of Utah Adult Services (1,788 clinicians)
- Catholic Health Initiatives Colorado (1,225 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,501
- Services billed
- 2,461
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,463 | 1,151 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 469 | 464 |
| Established patient office or other outpatient visit, 40-54 minutes | 212 | 181 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 104 | 45 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 98 | 98 |
| Heart muscle strain imaging | 92 | 91 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 91 | 91 |
| Established patient office or other outpatient visit, 30-39 minutes | 75 | 60 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 62 | 62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 44 | 44 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Salt Lake City, UT | 117 |
| Entresto (sacubitril/valsartan) Other prescribers in Salt Lake City, UT | 97 |
| Atorvastatin Calcium Other prescribers in Salt Lake City, UT | 82 |
| Torsemide Other prescribers in Salt Lake City, UT | 76 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Salt Lake City, UT | 73 |
| Furosemide Other prescribers in Salt Lake City, UT | 64 |
| Losartan Potassium Other prescribers in Salt Lake City, UT | 52 |
| Metoprolol Succinate Other prescribers in Salt Lake City, UT | 47 |
| Jardiance (empagliflozin) Other prescribers in Salt Lake City, UT | 45 |
| Carvedilol Other prescribers in Salt Lake City, UT | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 322 payments worth $320,001 in total to this clinician.
| Actelion Pharmaceuticals US, Inc. | $131,254 |
|---|---|
| United Therapeutics Corporation | $84,568 |
| Merck Sharp & Dohme LLC | $60,727 |
| Scpharmaceuticals Inc. | $31,974 |
| Bayer HealthCare Pharmaceuticals Inc. | $11,171 |
| Insmed, Inc. | $123 |
| Chiesi USA, Inc. | $110 |
| Novo Nordisk Inc | $34.86 |
| Compensation for services other than consulting (speaking, faculty) | $212,343 |
|---|---|
| Travel and Lodging | $50,372 |
| Honoraria | $28,525 |
| Consulting Fee | $22,160 |
| Food and Beverage | $6,601 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation May 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,560 |
| United Therapeutics Corporation Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) REMODULIN · Pulmonary Arterial Hypertension | $9,900 |
| Actelion Pharmaceuticals US, Inc. Jul 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $9,450 |
| United Therapeutics Corporation Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) ORENITRAM · Pulmonary Arterial Hypertension | $9,240 |
| United Therapeutics Corporation Oct 3, 2025 | Consulting Fee TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $8,200 |
| United Therapeutics Corporation Aug 8, 2025 | Consulting Fee REMODULIN · Pulmonary Arterial Hypertension | $8,200 |
| Scpharmaceuticals Inc. Jul 31, 2025 | Honoraria FUROSCIX · Cardiology | $7,000 |
| Scpharmaceuticals Inc. Aug 18, 2025 | Honoraria FUROSCIX · Cardiology | $6,300 |
| Scpharmaceuticals Inc. Dec 18, 2025 | Honoraria FUROSCIX · Cardiology | $6,300 |
| Scpharmaceuticals Inc. Oct 1, 2025 | Honoraria FUROSCIX · Cardiology | $6,300 |
All 216 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Scpharmaceuticals Inc. Dec 18, 2025 | Honoraria FUROSCIX · Cardiology | $6,300 |
| Scpharmaceuticals Inc. Dec 18, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to PHOENIX, AZ | $26.55 |
| Scpharmaceuticals Inc. Dec 2, 2025 | Honoraria FUROSCIX · Cardiology | $1,400 |
| Merck Sharp & Dohme LLC Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Nov 26, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Dallas, TX | $150 |
| Merck Sharp & Dohme LLC Nov 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Dallas, TX · in-kind | $410 |
| Merck Sharp & Dohme LLC Nov 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Dallas, TX · in-kind | $236 |
| United Therapeutics Corporation Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) REMODULIN · Pulmonary Arterial Hypertension | $9,900 |
| United Therapeutics Corporation Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,640 |
| United Therapeutics Corporation Nov 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Anchorage, AK · in-kind | $524 |
| United Therapeutics Corporation Nov 5, 2025 | Travel and Lodging travel to Denver, CO | $96.40 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $547 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Westminster, CO · in-kind | $201 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia; Adempas · Cardio-Renal | $4,147 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 31, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $248 |
| Scpharmaceuticals Inc. Oct 30, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to PHOENIX, AZ | $391 |
| Scpharmaceuticals Inc. Oct 30, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to PHOENIX, AZ | $253 |
| United Therapeutics Corporation Oct 30, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $249 |
| Scpharmaceuticals Inc. Oct 30, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to PHOENIX, AZ | $193 |
| Scpharmaceuticals Inc. Oct 30, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to PHOENIX, AZ | $80.00 |
| Merck Sharp & Dohme LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC Oct 22, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Missoula, MT | $150 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Missoula, MT · in-kind | $603 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Missoula, MT · in-kind | $497 |
| United Therapeutics Corporation Oct 16, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $235 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Missoula, MT · in-kind | $198 |
| Actelion Pharmaceuticals US, Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 10, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $80.00 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 10, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $60.18 |
| Actelion Pharmaceuticals US, Inc. Oct 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Wichita, KS · in-kind | $878 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 9, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $207 |
| Actelion Pharmaceuticals US, Inc. Oct 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Wichita, KS · in-kind | $187 |
| Actelion Pharmaceuticals US, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $675 |
| Actelion Pharmaceuticals US, Inc. Oct 8, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Washington, MO · in-kind | $480 |
| Actelion Pharmaceuticals US, Inc. Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Oct 6, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Seattle, WA | $306 |
| Actelion Pharmaceuticals US, Inc. Oct 6, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Seattle, WA | $241 |
| United Therapeutics Corporation Oct 3, 2025 | Consulting Fee TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $8,200 |
| Actelion Pharmaceuticals US, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX · in-kind | $256 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX · in-kind | $234 |
| United Therapeutics Corporation Oct 2, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Houston, TX | $63.68 |
| Scpharmaceuticals Inc. Oct 1, 2025 | Honoraria FUROSCIX · Cardiology | $6,300 |
| Scpharmaceuticals Inc. Oct 1, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to LAS VEGAS, NV | $148 |
| Actelion Pharmaceuticals US, Inc. Sep 26, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Washington, MO · in-kind | $260 |
| United Therapeutics Corporation Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) ORENITRAM · Pulmonary Arterial Hypertension | $9,240 |
| United Therapeutics Corporation Sep 18, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Little Rock, AR · in-kind | $268 |
| Actelion Pharmaceuticals US, Inc. Sep 17, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $481 |
| Actelion Pharmaceuticals US, Inc. Sep 17, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Wichita, KS · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Sep 16, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Wichita, KS · in-kind | $686 |
| Actelion Pharmaceuticals US, Inc. Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,050 |
| Scpharmaceuticals Inc. Sep 10, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to LAS VEGAS, NV | $180 |
| Actelion Pharmaceuticals US, Inc. Sep 8, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boise, ID · in-kind | $49.50 |
| Actelion Pharmaceuticals US, Inc. Sep 5, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Washington, MO · in-kind | $5.50 |
| United Therapeutics Corporation Sep 4, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $199 |
| Actelion Pharmaceuticals US, Inc. Sep 3, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Seattle, WA · in-kind | $554 |
| Actelion Pharmaceuticals US, Inc. Aug 29, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $5.50 |
| Scpharmaceuticals Inc. Aug 26, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to LAS VEGAS, NV | $441 |
| Scpharmaceuticals Inc. Aug 26, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to LAS VEGAS, NV | $80.00 |
| United Therapeutics Corporation Aug 22, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind | $180 |
| Scpharmaceuticals Inc. Aug 18, 2025 | Honoraria FUROSCIX · Cardiology | $6,300 |
| Actelion Pharmaceuticals US, Inc. Aug 18, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Scpharmaceuticals Inc. Aug 18, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to BOSTON, MA | $382 |
| Scpharmaceuticals Inc. Aug 18, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to DENVER, CO | $127 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 17, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $275 |
| Actelion Pharmaceuticals US, Inc. Aug 16, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Kansas City, MO · in-kind | $434 |
| Actelion Pharmaceuticals US, Inc. Aug 15, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Kansas City, MO · in-kind | $184 |
| Actelion Pharmaceuticals US, Inc. Aug 15, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Kansas City, MO · in-kind | $173 |
| Actelion Pharmaceuticals US, Inc. Aug 13, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Washington, MO · in-kind | $5.50 |
| United Therapeutics Corporation Aug 8, 2025 | Consulting Fee REMODULIN · Pulmonary Arterial Hypertension | $8,200 |
| United Therapeutics Corporation Aug 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind | $1,023 |
| United Therapeutics Corporation Aug 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind | $345 |
| United Therapeutics Corporation Aug 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX | $39.68 |
| United Therapeutics Corporation Aug 5, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind | $473 |
| Actelion Pharmaceuticals US, Inc. Aug 5, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Washington, MO · in-kind | $250 |
| Scpharmaceuticals Inc. Jul 31, 2025 | Honoraria FUROSCIX · Cardiology | $7,000 |
| Actelion Pharmaceuticals US, Inc. Jul 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Jul 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $5.50 |
| Merck Sharp & Dohme LLC Jul 18, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to SALT LAKE CITY, UT | $25.00 |
| Scpharmaceuticals Inc. Jul 17, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to DENVER, CO | $259 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| United Therapeutics Corporation Jul 14, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Little Rock, AR · in-kind | $773 |
| Actelion Pharmaceuticals US, Inc. Jul 14, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Chesterfield, MO · in-kind | $180 |
| Actelion Pharmaceuticals US, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Jul 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Chesterfield, MO · in-kind | $642 |
| Actelion Pharmaceuticals US, Inc. Jul 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Chesterfield, MO · in-kind | $275 |
| United Therapeutics Corporation Jul 9, 2025 | Compensation for services other than consulting (speaking, faculty) REMODULIN · Pulmonary Arterial Hypertension | $3,960 |
| Actelion Pharmaceuticals US, Inc. Jul 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Washington, MO · in-kind | $616 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 9, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $22.11 |
| Actelion Pharmaceuticals US, Inc. Jul 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boise, ID · in-kind | $5.50 |
| Merck Sharp & Dohme LLC Jul 8, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to SALT LAKE CITY, UT · in-kind | $437 |
| Actelion Pharmaceuticals US, Inc. Jul 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $9,450 |
| Actelion Pharmaceuticals US, Inc. Jul 2, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boise, ID · in-kind | $5.50 |
| United Therapeutics Corporation Jun 27, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Boise, ID · in-kind | $215 |
| Actelion Pharmaceuticals US, Inc. Jun 27, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boise, ID · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Jun 26, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boise, ID · in-kind | $546 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Consulting Fee | $5,760 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Travel and Lodging travel to Denver, CO | $150 |
| Scpharmaceuticals Inc. Jun 24, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to DENVER, CO | $261 |
| Scpharmaceuticals Inc. Jun 24, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to DENVER, CO | $80.00 |
| Actelion Pharmaceuticals US, Inc. Jun 24, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ivins, UT | $40.00 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia; Adempas · Cardio-Renal | $4,510 |
| Actelion Pharmaceuticals US, Inc. Jun 23, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Kansas City, MO · in-kind | $645 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 19, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Aurora, CO · in-kind | $289 |
| Actelion Pharmaceuticals US, Inc. Jun 17, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ivins, UT · in-kind | $234 |
| Scpharmaceuticals Inc. Jun 16, 2025 | Honoraria FUROSCIX · Cardiology | $1,225 |
| Actelion Pharmaceuticals US, Inc. Jun 16, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $231 |
| Actelion Pharmaceuticals US, Inc. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Jun 13, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $963 |
| Actelion Pharmaceuticals US, Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Jun 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ivins, UT · in-kind | $243 |
| Actelion Pharmaceuticals US, Inc. Jun 8, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ivins, UT · in-kind | $492 |
| Actelion Pharmaceuticals US, Inc. Jun 4, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Hutchinson, KS · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Jun 3, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Hutchinson, KS · in-kind | $661 |
| United Therapeutics Corporation Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) REMODULIN · Pulmonary Arterial Hypertension | $3,960 |
| Merck Sharp & Dohme LLC May 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Denver, CO · in-kind | $497 |
| Merck Sharp & Dohme LLC May 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Denver, CO · in-kind | $295 |
| United Therapeutics Corporation May 28, 2025 | Travel and Lodging travel to Anchorage, AK | $30.82 |
| Actelion Pharmaceuticals US, Inc. May 23, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,350 |
| United Therapeutics Corporation May 23, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Portland, OR | $53.59 |
| United Therapeutics Corporation May 23, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Portland, OR | $40.00 |
| Actelion Pharmaceuticals US, Inc. May 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $273 |
| Actelion Pharmaceuticals US, Inc. May 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $143 |
| Merck Sharp & Dohme LLC May 21, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Merck Sharp & Dohme LLC May 21, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Idaho Falls, ID | $150 |
| United Therapeutics Corporation May 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,560 |
| Merck Sharp & Dohme LLC May 16, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| United Therapeutics Corporation May 16, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Portland, OR · in-kind | $270 |
| Merck Sharp & Dohme LLC May 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to KALISPELL, MT | $150 |
| Actelion Pharmaceuticals US, Inc. May 16, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Chesterfield, MO · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| United Therapeutics Corporation May 9, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Boise, ID · in-kind | $513 |
| Merck Sharp & Dohme LLC May 8, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Idaho Falls, ID · in-kind | $1,114 |
| Merck Sharp & Dohme LLC May 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to KALISPELL, MT · in-kind | $1,341 |
| Merck Sharp & Dohme LLC May 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to KALISPELL, MT · in-kind | $859 |
| Actelion Pharmaceuticals US, Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $675 |
| Merck Sharp & Dohme LLC May 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to KALISPELL, MT · in-kind | $197 |
| United Therapeutics Corporation May 6, 2025 | Compensation for services other than consulting (speaking, faculty) REMODULIN · Pulmonary Arterial Hypertension | $3,960 |
| Actelion Pharmaceuticals US, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,350 |
| United Therapeutics Corporation May 3, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind | $571 |
| United Therapeutics Corporation May 2, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Seattle, WA | $104 |
| Actelion Pharmaceuticals US, Inc. May 1, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Chesterfield, MO · in-kind | $586 |
| Actelion Pharmaceuticals US, Inc. Apr 30, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ivins, UT · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Apr 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ivins, UT · in-kind | $364 |
| Actelion Pharmaceuticals US, Inc. Apr 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boston, MA · in-kind | $355 |
| Actelion Pharmaceuticals US, Inc. Apr 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boston, MA · in-kind | $162 |
| Actelion Pharmaceuticals US, Inc. Apr 27, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boston, MA · in-kind | $134 |
| Merck Sharp & Dohme LLC Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| United Therapeutics Corporation Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $3,960 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Las Vegas, NV | $150 |
| Actelion Pharmaceuticals US, Inc. Apr 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,363 |
| Merck Sharp & Dohme LLC Apr 17, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Las Vegas, NV · in-kind | $678 |
| Merck Sharp & Dohme LLC Apr 17, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Las Vegas, NV · in-kind | $194 |
| Actelion Pharmaceuticals US, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| United Therapeutics Corporation Apr 16, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Portland, OR · in-kind | $273 |
| Actelion Pharmaceuticals US, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| United Therapeutics Corporation Apr 15, 2025 | Travel and Lodging travel to Anchorage, AK · in-kind | $40.31 |
| Actelion Pharmaceuticals US, Inc. Apr 14, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $951 |
| Actelion Pharmaceuticals US, Inc. Apr 12, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $291 |
| Actelion Pharmaceuticals US, Inc. Apr 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $454 |
| United Therapeutics Corporation Apr 10, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Seattle, WA · in-kind | $244 |
| Actelion Pharmaceuticals US, Inc. Apr 10, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Apr 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boston, MA · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Apr 9, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $5.50 |
| United Therapeutics Corporation Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) REMODULIN · Pulmonary Arterial Hypertension | $3,960 |
| Actelion Pharmaceuticals US, Inc. Apr 1, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $235 |
| Actelion Pharmaceuticals US, Inc. Mar 27, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI | $948 |
| United Therapeutics Corporation Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,840 |
| Actelion Pharmaceuticals US, Inc. Mar 25, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Boston, MA · in-kind | $863 |
| United Therapeutics Corporation Mar 21, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Portland, OR · in-kind | $238 |
| Merck Sharp & Dohme LLC Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $5,760 |
| Actelion Pharmaceuticals US, Inc. Mar 19, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,363 |
| Actelion Pharmaceuticals US, Inc. Mar 14, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $1,198 |
| Actelion Pharmaceuticals US, Inc. Mar 14, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $523 |
| Actelion Pharmaceuticals US, Inc. Mar 13, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $579 |
| Merck Sharp & Dohme LLC Mar 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA | $150 |
| Actelion Pharmaceuticals US, Inc. Mar 13, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Mar 12, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $414 |
| Actelion Pharmaceuticals US, Inc. Mar 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Springfield, MA · in-kind | $872 |
| Actelion Pharmaceuticals US, Inc. Mar 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Reno, NV · in-kind | $537 |
| Actelion Pharmaceuticals US, Inc. Mar 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Webster Groves, MO · in-kind | $480 |
| Merck Sharp & Dohme LLC Mar 8, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $229 |
| Actelion Pharmaceuticals US, Inc. Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $1,350 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $560 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $229 |
| Merck Sharp & Dohme LLC Mar 7, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $169 |
| Actelion Pharmaceuticals US, Inc. Mar 5, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $5.50 |
| United Therapeutics Corporation Mar 4, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Idaho Falls, ID · in-kind | $15.91 |
| Actelion Pharmaceuticals US, Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,050 |
| United Therapeutics Corporation Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) ORENITRAM · Pulmonary Arterial Hypertension | $1,270 |
| United Therapeutics Corporation Feb 25, 2025 | Travel and Lodging travel to Wasilla, AK · in-kind | $929 |
| Actelion Pharmaceuticals US, Inc. Feb 24, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $740 |
| Actelion Pharmaceuticals US, Inc. Feb 20, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Grand Rapids, MI · in-kind | $477 |
| Actelion Pharmaceuticals US, Inc. Feb 19, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $5.50 |
| United Therapeutics Corporation Feb 11, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Seattle, WA · in-kind | $378 |
| United Therapeutics Corporation Feb 5, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $518 |
| Actelion Pharmaceuticals US, Inc. Jan 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Little Rock, AR · in-kind | $680 |
| Actelion Pharmaceuticals US, Inc. Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| United Therapeutics Corporation Jan 27, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Portland, OR · in-kind | $15.94 |
| Merck Sharp & Dohme LLC Jan 24, 2025 | Compensation for services other than consulting (speaking, faculty) WINREVAIR · CARDIOVASCULAR | $3,840 |
| Actelion Pharmaceuticals US, Inc. Jan 24, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Little Rock, AR · in-kind | $851 |
| Actelion Pharmaceuticals US, Inc. Jan 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Little Rock, AR · in-kind | $623 |
| Actelion Pharmaceuticals US, Inc. Jan 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Little Rock, AR · in-kind | $159 |
| Actelion Pharmaceuticals US, Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Jan 17, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Pocatello, ID · in-kind | $897 |
| Actelion Pharmaceuticals US, Inc. Jan 16, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Ogden, UT · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Jan 15, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Pocatello, ID · in-kind | $5.50 |
| United Therapeutics Corporation Jan 8, 2025 | Travel and Lodging travel to Great Falls, MT · in-kind | $463 |
| Actelion Pharmaceuticals US, Inc. Jan 6, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Pocatello, ID · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Jan 2, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Little Rock, AR · in-kind | $5.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $776,963 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC - A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Merck Sharp & Dohme LLC - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate th…
Novartis Pharmaceuticals Corporation - Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Liquidia Technologies, Inc. · Completed · NCT03399604 - BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV…
Bayer HealthCare Pharmaceuticals Inc. - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.